Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 11
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Colijn, Mark A. Nitta, Bradley H. and Grossberg, George T. 2015. Psychosis in Later Life. Harvard Review of Psychiatry, Vol. 23, Issue. 5, p. 354.

    Greenblatt, H. Karl and Greenblatt, David J. 2016. Use of Antipsychotics for the Treatment of Behavioral Symptoms of Dementia. The Journal of Clinical Pharmacology, Vol. 56, Issue. 9, p. 1048.

    Schwarz, Stefan Froelich, Lutz and Burns, Alistair 2012. Pharmacological treatment of dementia. Current Opinion in Psychiatry, Vol. 25, Issue. 6, p. 542.

    Desai, Abhilash K. Schwartz, Lori and Grossberg, George T. 2012. Behavioral Disturbance in Dementia. Current Psychiatry Reports, Vol. 14, Issue. 4, p. 298.

    Žmuc Veranič, Lea Pregelj, Peter and Jerin, Aleš 2015. Treating agitation and aggression in patients with Alzheimer's disease with escitalopram. Psychogeriatrics, p. n/a.

    Magierski, Radoslaw and Sobow, Tomasz 2016. Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia. Expert Review of Neurotherapeutics, Vol. 16, Issue. 4, p. 375.

    McClam, Tamela D. Marano, Christopher M. Rosenberg, Paul B. and Lyketsos, Constantine G. 2015. Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer’s Disease. Harvard Review of Psychiatry, Vol. 23, Issue. 5, p. 377.

    Porsteinsson, Anton P Keltz, Melanie A and Smith, Jessica S 2014. Role of citalopram in the treatment of agitation in Alzheimer's disease. Neurodegenerative Disease Management, Vol. 4, Issue. 5, p. 345.

    Seitz, Dallas P. Gill, Sudeep S. Herrmann, Nathan Brisbin, Sarah Rapoport, Mark J. Rines, Jenna Wilson, Kimberley Le Clair, Ken and Conn, David K. 2013. Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. International Psychogeriatrics, Vol. 25, Issue. 02, p. 185.

    Porsteinsson, Anton P Smith, Jessica S Keltz, Melanie A and Antonsdottir, Inga M 2014. Can antidepressant medication relieve agitation in Alzheimer’s disease?. Expert Review of Neurotherapeutics, Vol. 14, Issue. 9, p. 969.

    Wilkins, James M. and Forester, Brent P. 2016. Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia. Current Psychiatry Reports, Vol. 18, Issue. 2,


Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study

  • Yoram Barak (a1), Igor Plopski (a1), Shelly Tadger (a1) and Diana Paleacu (a1)
  • DOI:
  • Published online: 15 April 2011

Background: Antipsychotics are frequently used to treat psychosis, aggression and agitation in patients with Alzheimer's disease (AD), but safety warnings abound. Escitalopram was investigated since citalopram has demonstrated some effectiveness in AD. We compared escitalopram and risperidone for psychotic symptoms and agitation associated with AD.

Methods: Inpatients with AD, who had been hospitalized because of behavioral symptoms, were recruited to a six-week randomized, double-blind, controlled trial. Participants (n = 40) were randomized to once daily risperidone 1 mg or escitalopram 10 mg.

Results: The NPI total score improved in both groups. Onset was earlier in the risperidone-treated group, but improvement did not significantly differ between groups by study end. Completion rates differed for escitalopram (75%) and risperidone (55%), mainly due to adverse events. There were no adverse events in the escitalopram group, while in the risperidone group two patients suffered severe extrapyramidal symptoms and four patients suffered acute physical illness necessitating transfer to general hospital.

Conclusion: Escitalopram and risperidone did not differ in efficacy in reducing psychotic symptoms and agitation in patients with AD. Completion rates were higher for escitalopram-treated patients. Replication in larger trials with ambulatory patients is needed.

Corresponding author
Correspondence should be addressed to: Yoram Barak, MD, MHA, Director of Psychogeriatrics, Abarbanel MHC, 15 KKL Street, Bat-Yam, 59100, Israel. Phone and Fax: +972-3-5552738. Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

C. Ballard and R. Howard (2006). Neuroleptic drugs in dementia: benefits and harm. Nature Reviews Neuroscience, 7, 492500.

J. L. Cummings , M. Mega , K. Gray , S. Rosenberg-Thompson , D. A. Carusi and J. Gornbein (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 23082314.

M. F. Folstein , S. E. Folstein and P. R. McHugh (1975). “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189198.

P. Gorwood , E. Weiller , O. Lemming and C. Katona (2007). Escitalopram prevents relapse in older patients with major depressive disorder. American Journal of Geriatric Psychiatry, 15, 581593.

M. Margallo-Lana (2001). Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. International Journal of Geriatric Psychiatry, 16, 3944.

O. Mnie-Filali (2007). R-citalopram prevents the neuronal adaptive changes induced by escitalopram. Neuroreport, 18, 15531556.

A. L. Nyth and C. G. Gottfries (1990). The clinical efficacy of citalopram in treatment of emotional disturbances of dementia disorders: a Nordic multicentre study. British Journal of Psychiatry, 157, 894901.

B. G. Pollock (2002). Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. American Journal of Psychiatry, 159, 460465.

L. S. Schneider for the CATIE-AD Study Group (2006). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine, 355, 15251538.

E. Wu , P. E. Greenberg , E. Yang , A. Yu and M. H. Erder (2008). Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Current Medical Research Opinion, 24, 25872595.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *